Objectives: This purpose of this review is to assess the safety and effectiveness of intralesional treatments for plantar warts, including immunotherapies and drugs that modulate the immune system or have anti-viral properties. Background: The lack of a therapy that works for everyone makes plantar wart maintenance difficult. Emerging as a viable option, intralesional treatments provide distinct benefits when dealing with many or resistant lesions. In order to cure plantar warts caused by the human papillomavirus, this review delves into the various intralesional medicines and how they work (HPV). Locations of the Data Sets: Research on intralesional therapies for plantar warts up to the year 2023 was scoured via a variety of Medline databases, including PubMed. Research on the effectiveness, side effects, and action mechanisms of various intralesional medicines that met certain inclusion criteria were taken into consideration for this review. To be considered for inclusion in the study, research had to be written and published in English, undergo peer review, and give light on the processes and effectiveness of intralesional therapies for plantar warts. A comprehensive examination of the study's quality, including its ethical clearance, eligibility requirements, controls, and outcome assessment tools, was required for data extraction. Conclusions: There is a wide range of intralesional therapies available for plantar warts, each with its own set of advantages and disadvantages in terms of safety and effectiveness. This study provides an overview of the current state of knowledge about the treatment of plantar warts caused by HPV, including the methods and results of immunotherapies, mycobacterial agents, Candida antigen, and other intralesional agents.